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Ewing’s tumour family of the soft tissues in children: 
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I n t r o d u c t i o n .  Peripheral primitive neuroectodermal tumour (PNET) and extraosseous Ewing’s sarcoma (EES) are 
rare paediatric malignancies, which, clinically, are regarded as partially chemosensitive neoplasms.
M a t e r i a l  a n d  m e t h o d s .  We performed a retrospective analysis o f clinical data collected in the coordinating centre. A ll 
patients were under the age o f 19 and presented with PN ET (36 cases) or EES (8 cases). They were treated according to the 
CWS-91, SIOP-MMT-91 or CWS-96 protocols. The primary tumour was localized within the head/neck region in 8 cases 
(18.2%), in 11 cases (25%) within the chest wall, in 3 cases (6.8%) in the abdomen, in 8 cases (18.2%) paraspinally, in 5 
cases (11.4%) within the pelvis, and in 9 cases (20.5%) on the extremities. In 10 patients (22.7%) distant metastases were 
present at the time o f diagnosis.
R e s u l t s .  32 children (72.7%) achieved complete remission with relapse in 16 cases -  local failure in 9, distant failure in 3 
and mixed in 4 cases. Response to chemotherapy was observed in 83.3% subjects: in 16.7% -  complete, in 33.3% -  good and 
in 33.3% -  partial. The remaining 16.7% did not respond to chemotherapy. 5-year event-free survival (EFS) and overall 5-year 
survival estimate (OS) for all analysed patients was 0.39±0.08 and 0.44±0.08, respectively. Patients treated according to the 
CWS-96 protocol had a slightly better prognosis as compared to children treated according to the CWS-91/SIOP-MMT-91 
protocols. Important factors influencing prognosis were gender, disease stage, and tumour localization.
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C o n c l u s i o n s .  Tumours localized within the abdomen and the extremities, as well as the presence o f distant metastases, are 
important unfavorable prognostic indicators. Radiotherapy and radical surgery supporting intensive chemotherapy could reduce 
the risk o f relapse.
Rodzina guzów Ewinga w obrębie tkanek miękkich u dzieci: 
11-letnie doświadczenie Polskiej Pediatrycznej Grupy Guzów Litych
W p r o w a d z e n i e .  Obwodowy pierwotny guz neuroektodermalny oraz pozakostny mięsak Ewinga należą do rzadkich 
złośliwych nowotworów u dzieci. Klinicznie guzy traktowane te są jako częściowo wrażliwe na chemioterapię.
M a t e r i a ł  i m e t o d a .  Wpracy dokonano retrospektywnej analizy danych klinicznych pacjentów zgłoszonych do ośrodka 
koordynującego. Wszyscy pacjenci byli w wieku poniżej 19 lat i u wszystkich rozpoznano obwodowy pierwotny guz 
neuroektodermalny lub pozakostnego mięsaka Ewinga. Leczenie było przeprowadzone w oparciu o następujące protokoły 
lecznicze: CWS-91, SIOP-MMT-91 lub CWS-96. U 36 osób rozpoznano PNET, natomiast u 8 EES. Guz pierwotny 
zlokalizowany był u 8 pacjentów (18,2%) w obrębie głowy/szyi, u 11 (25%) w zakresie ściany klatki piersiowej, u 3 (6,8%) 
w jamie brzusznej, u 8 (18,2%) przyrdzeniowo, u 5 (11,4%) w miednicy, i u 9 (20,5%) w obrębie kończyn. U 10 dzieci (22,7%) 
w momencie diagnozy stwierdzono obecność przerzutów odległych.
Wy n ik i .  32 osoby (72,7%) uzyskały całkowitą remisję. Wśród 16 pacjentów, którzy uzyskali pełną remisję, wystąpił nawrót 
choroby: u 9 stwierdzono wznowę lokalną, u 3 przerzutową i u 4 mieszaną. Po pierwszym cyklu chemioterapii, 83,3% guzów 
odpowiedziało na zastosowaną chemioterapię: w 16,7% zaobserwowaną pełną odpowiedź, w 33,3% dobrą i w 33,3% 
częściową. Pozostałe 6,7% guzów nie zareagowało na chemioterapię. 5-letnie przeżycie wolne od choroby (EFS) i całkowite 
przeżycie (OS) dla wszystkich analizowanych pacjentów wyniosło odpowiednio 0,39±0,08 i 0.44±0,08. Pacjenci leczeni 
zgodnie z  protokołem CWS-96 charakteryzowali się nieznacznie lepszym rokowaniem w stosunku do pacjentów leczonych 
według protokołu CWS-91/SIOP-MMT-91. Czynnikami wpływającymi na przeżycie były płeć, stadium choroby i lokalizacja 
ogniska pierwotnego.
W n i o s k i .  Lokalizacja nowotworu w obrębie jamy brzusznej i kończyn, ja k  również obecność przerzutów odległych były 
istotnymi niekorzystnymi parametrami rokowniczymi. Radioterapia i radykalny zabieg chirurgiczny, wspomagające 
chemioterapię, mogą obniżyć ryzyko nawrotu choroby.
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Introduction
Peripheral primitive neuroectodermal tumour (PNET) 
and extraosseous Ewing’s sarcoma (EES) account for 
approximately 10% of all paediatric soft tissue sarcomas 
[1]. They present as small round cell malignancies of 
neural crest origin. The tumor cells typically demonstrate 
expression of M IC2 (CD99) and p2 microglobulin, 
a presence of neuronal markers (neurospecific enolase 
-  NSE, S-100 protein, neurofilaments and others), and/or 
form Home-Wright rosettes [1, 2]. Previously the two 
entities were distinguished basing on immunochemistry 
and microspopic examination. If tumour cells presented 
with at least two neuronal markers and/or formed Home- 
Wright rosettes, the neoplasm was classified as PNET; if 
there was no or only one neuronal m arker, Ewing’s 
sarcoma was diagnosed. Nowadays both tum ours are 
classified as the Ewing’s family tumours, as it was shown 
that they both dem onstrate specific chromosomal 
aberrations: t(11;22) or t(21;22) with formation of specific 
fusion genes, and show several immunohistochemical 
reactions typical only for Ewing’s family tumours [1, 3].
Clinically, both tumours are regarded as partially 
chemosensitive malignancies [4-7]. The most common 
localisations include the trunk, the extremities and the 
head and neck. The treatment of Ewing’s family tumours 
in children consists of a com bination of multi-agent
chemotherapy, radiotherapy and surgical removal of the 
primary tumor [4-7]. Although during the last 20 years 
a significant improvement of outcome was achieved in 
this group of patients the mortality rate remains high. 
Below we present a multicenter study demonstrating our 
experiences in the diagnosis and treatment of 44 children 
and adolescents suffering from Ewing’s family tumours.
Material and methods
P a t i e n t s  c h a r a c t e r i s t i c s
The analysed data were collected over a decade, beginning with 
the year 1991 in institutions collaborating with the Polish 
Paediatric Solid Tumours Group. A t the time of diagnosis the 
patients were under 19 years of age. In all cases we recognised 
peripheral primary neuroectodermal tumours or extraosseous 
Ewing’s sarcomas. Institutional ethical review and informed 
consent were obtained from all patients. The median follow up 
was 26 months (range: 4 -  117 months) for all patients and 
40 months (range: 4 -  117 months) for surviving patients.
Over the study period (1991-2002) 306 children with soft 
tissue sarcomas were registered at the coordinating centre. Of 
these 36 (11.8%) presented with PNET and 8 (2.6%) with EES. 
Their age ranged from 6 to 210 months (mean: 117.2±66 
months, median: 124.5 months); 21 subjects (47.7%) were below 
the age of 10, and 23 (52.3%) were older than 10 years. No 
gender predominance was observed: there were 22 boys (50%) 
and 22 girls (50%). D etailed patient characteristics have been 
presented in Table I.
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Table I. Patient characteristics
Characteristic Number of 
patients (%)
Total 44 (100%)
Diagnosis:
-  Peripheral primitive neuroectoderm al tumour (PNET) 36 (81.8%)
-  Extraosseus Ewing’s sarcoma (EES) 8 (18.2%)
Treatment:
-  CWS-91 Protocol 13 (29.6%)
-  SIOP-MMT-89 Protocol 2 (4.5%)
-  CWS-96 Protocol 29 (65.9%)
Age:
-  M edian value 124.5 months
-  <10 age 21 (47.7%)
-  >10 age 23 (52.3%)
Gender:
-  Boys 22 (50%)
-  Girls 22 (50%)
Tumour localization:
-  Head/neck region 8 (18.2%)
-  Chest wall 11 (25%)
-  Abdomen 3 (6.8%)
-  Paraspinal 8 (18.2%)
-  Pelvis 5 (11.4%)
-  Extremities 9 (20.5%)
Tumour size
-  <5 cm 9 (20.5%)
-  >5 cm 33 (75%)
-  no data 2 (4.5%)
Tumour stage
-  II (localized disease, microscopic rests after resection) 7 (15.9%)
-  III (localized disease, macroscopic rests after resection) 27 (61.4%)
-  IV  (distant metastases) 10 (22.7%)
Regional lymph nodes involvement:
-  Yes 10 (22.7%)
-  No 34 (87.3%)
Metastases localization:
-  Lungs 6
-  Bones 3
-  Non-regional lymph nodes 3
-  Liver 2
-  Bone marrow 2
-  Pleura 1
-  Central nervous system 1
-  Right upper arm 1
T r e a t m e n t
Over the last decade different modalities were applied in the 
treatm ent of childhood Ewing’s family tumours of soft tissues. 
In the early nineties (1991-1995) two protocols were in use: 
the CWS-91 protocol (13 patients) for stage I-III [4] and the 
SIOP-MMT-89 protocol for stage IV  -  (2 patients) [5]. From 
1996 onward the CWS-96 protocol (29 patients) [6] was used for 
all patients (Table I). All these protocols present combinations 
of multi-agent chem otherapy, radiotherapy and primary 
or/and secondary surgical tum our removal. They all involve 
combinations of vincristine, actinomycine D , doxorubicin, 
epirubicine, ifosfamide, cyclofosfamide, carboplatine, cis-platin 
and etoposide. Combinations of VACA (VCR, A D R , CY, 
AMD), EVAIA (VP-16, VCR, ADR, AMD, IFO) and CEVAIE
(CARBO, EPI, IFO, AMD, VCR, VP16) have been adopted in 
the CWS protocols and high-dose chemotherapy -  Cy/thiotepa 
and melphalan/VP-16 with hem atopoietic stem cell rescue 
or oral m aintenance therapy with VP-16/ idarubicin and 
trophosphamide have been investigated in metastatic patients. 
The intensity, duration and type of chemotherapy were stratified 
according to the risk groups defined basing on histology, site 
and TNM status. In the CWS-91 subpopulation patients from 
group A  and B received VACA and patients from group C, i.e. 
with poor prognosis -  the EVAIA protocol. In the CWS-96 
protocol the chemotherapeutic regimen has been risk-adapted 
and stratified according to TNM, prim ary resectability 
and histology. Patients in the low risk group received only VCR 
and AMD. S tandard risk patients w ere adm inistered VCR, 
AM D and IFO  (IVA). Patients in the high risk group were 
adm inistered CEVAIE -  six drug cycles. R adiation was an 
effective method of achieving local tum or control in patients 
with microscopic or gross residual disease following surgical 
resection or chem otherapy. R ecom endations for radiation 
depended on the primary site and size, histology, age and the 
extent of disease before and after surgical resection. Irradiation 
was avoided in young children (<  3 years), whenever possible, 
because of its adverse effects on growth. According to the 
protocols, radiotherapy was commenced during chemotherapy in 
the 13th-14 th week of treatm ent (CWS-91) or during the 
10th-11 th week of treatm en t (CWS-96). R adiotherapy was 
individually considered in small children (below the age of 4) 
depending on the response to chemotherapy. The CWS studies 
recommended accelerated hyperfractionated irradiation (2x1.6 
Gy daily). According to the CWS-91 protocol the patients were 
irradiated with 32 Gy/48 Gy and according to the CWS-96 -  
with 32 Gy/44.8 Gy. Second-look surgery was stipulated whene­
ver the tumour was considered primarily non-resectable in any 
imaging technique: computed tomography (CT) or magnetic 
resonance tomography (MRT). None of the patients had been 
previously treated for any other malignancy.
Treatment response was evaluated after the first cycle of 
chemotherapy in all patients with disease stage III and IV. If 
the tumour was not present in any results of imaging diagnostics 
(CT, MRT or sonography) and all metastatic lesions cleared, 
the patients were assigned to the “complete response” group. 
Patients with tumour regression down to 1/3 or less of the initial 
tum our volume were classified as “good responders”. Patients 
with tum our size of less than 2/3 bu t m ore than 1/3 of the 
primary tumour volume were assigned to the “partial responding” 
group. The group of “non responders” consisted of all patients 
with progression or stabilisation of the disease and/or with 
tumour regression by less than 1/3 of the initial tumour volume.
R e l a p s e
“Local relapse” was defined as recurrence of the disease at the 
site of the primary tumour. Relapse was considered “regional” if 
the malignancy appeared in the regional lymph node or “distant” 
if it was found in any other localisation. If relapse involved more 
than one of groups mentioned above, it was considered a “mixed 
relapse”.
S t a t i s t i c a l  a n a l y s i s
D ata available by May 2002 was analysed using Statistical 97 PL 
for Windows software. Kaplan-M eier overall survival (OS) was 
calculated from the onset of therapy until the latest follow-up or 
death from any cause, Kaplan-Meier event-free survival (EFS) -  
from the onset of therapy until the time of treatm ent failure 
[8]. Failure was defined as relapse or death from any cause. The 
differences between the curves were estimated by F  Cox test 
and p-values less than 0.05 were considered statistically 
significant.
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Results
At the time of analysis 23 subjects (52.3%) were still alive. 
The detailed outcome analysis according to the disease 
stage is presented in Table II. 32 children (72.7%) 
achieved complete clinical remission (CCR) after first 
line treatment. In 16 individuals, who had achieved CCR 
(36.4%) relapse occurred: local relapse in 9 cases 
(20.5%), distant relapse in 3 cases (6.8%) and mixed 
relapse in 4 cases (9.1%). The remaining 16 (36.4%) pts 
are still in 1st CCR. In 4 cases (9.1%) partial remission 
was docum ented while in 8 cases (18.2%) we noted 
progression.
Table II. Final outcome according to the stage of disease
Stage II Stage III Stage IV
Surviving patients: 6 12 5
-  First complete remission 6 8 2
-  Partial remission - 2 1
-  Local relapse - 1* 1
-  M etastatic relapse - - 1**
-  Mixed relapse - 1 -
Deceased patients: 1 15 5
-  Partial remission - 1*** -
-  Local relapse - 6 1
-  M etastatic relapse - 1 1
-  Mixed relapse - 2 1
-  Progression 1 5 2
* The patient achieved second complete remission 
** The patient achieved second complete remission 
*** The patient died because of acute brain oedema
A fter the first cycle of chem otherapy 30 patients 
with stage III and IV disease were assessed according to 
treatm ent response. 5 patients (16.7%) responded 
completely to the employed treatment, 10 (33.3%) were 
classified as good responders, in 10 cases (33.3%) partial 
response was observed, and the remaining 5 children 
(16.7%) were classified as non-responders.
R adiotherapy was adm inistered to 31 patients 
(70.5%) -  the dose range varying from 22.5 to 58 Gy 
(mean: 42.2±9.0 Gy). 12 patients received hyper­
fractionated irradiation and 19 subjects -  standard 
irradiation. The treatm ent results according to the 
administered radiotherapy are presented in the Table III. 
The most common reasons for not administering 
radiotherapy were: patient age below 4 years or lack 
parental consent.
Second-look surgery was performed in 17 children 
(38.6%). In 2 children with stage III disease second-look 
surgery was limited to biopsy only, which revealed no 
residual tumour (histological complete remission), and 
in another patient only the m etastases were radically 
removed, as no residual tum our was discerned on 
imaging. All these 3 patients remain in first complete 
remission. In 6 patients m utilating resection of the 
primary tumour was performed, however only in 2 cases 
the resection was radical. 1 patient is still alive and in 
com plete remission and 1 (in stage IV) died due to 
disease progression. In 3 patients microscopic, and in 1 
patient macroscopic tumour residue was found; all these 
patients died: 2 due to local relapse, 1 due to mixed 
relapse and 1 due to rapid disease progression. Another 8 
patients underwent non-mutilating surgery, which was 
radical only in 3 cases. Unfortunately, all these patients 
died: 2 because of local relapse and 1 because of 
metastatic relapse. In 3 patients microscopic residuum 
was observed (all these patients died) and in 2 cases -  
macroscopic residue (one patient is still alive in CCR 
and one died due to local relapse).
5-year event-free survival (EFS) and overall 5-year 
survival estimate (OS) for all the patients was 0.39±0.08 
and 0.44±0.08, respectively. Patients treated according 
to the CWS-96 protocol had slightly better prognosis as 
com pared to children treated  according to the CWS- 
91/SIOP-MMT-91 protocol (5-year EFS 0.41 and 0.27, 
respectively, p=0.03; 5-year OS 0.44 and 0.4, respectively, 
p = 0.09). Having analysed several clinical parameters we 
state that the most im portant factors influencing
Table III. Final results of treatm ent according to the adm inistered radiotherapy
No radiotherapy Standard radiotherapy Hyperfractionated radiotherapy
Surviving patients: 5 10 8
-  First complete remission 3 6 7
-  Partial remission 2 1 -
-  Local relapse - 1 1**
-  M etastatic relapse - 1* -
-  Mixed relapse - 1 -
Decreased patients: 8 9 4
-  Partial remission 1*** - -
-  Local relapse - 6 1
-  M etastatic relapse 1 1 -
-  Mixed relapse - 1 2
-  Progression 6 1 1
* The patient achieved second complete remission 
** The patient achieved second complete remission 
*** The patient died because of acute brain oedema
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prognosis are gender (boys vs. girls: 5-year EFS 0.28 and 
0.38, respectively, p = 0.04; 5-year OS 0.31 and 0.58 
respectively, p = 0.02), stage of disease (Figure 1), and 
tumour localization (Figure 2). The best outcomes were 
observed in patients with stage II disease (stage II vs. 
stage III: p<0.01; stage II vs. stage IV: p<0.01), and 
poorer prognosis was found in patients with stage IV 
disease, although the difference between stage IV and 
stage III was not statistically significant (p = 0.47) 
(Figure 1). W hen comparing different tum our locali­
zations the best survival ratio was found in the case of 
tumours located within the pelvis and paraspinally. Very 
poor outcome was observed in patients with neoplasms 
within the abdomen and the extremities -  in the case of 
these localisations we did not observe survivals exceeding 
5 years (Figure 2). We observed no impact on survival of
the tumour, as compared to patients who responded only 
partially or were classified as non-responders although 
the difference was not significant (Figure 3). In 7 patients 
with disease stage III and IV we had insufficient data to 
evaluate the response after the 1st cycle of chemotherapy. 
Radiotherapy had significant influence on the final results 
of therapy (Table III, Figure 4). Patients treated with any 
kind of radiotherapy presented with a significantly better 
survival ratio as compared to patients who did not receive 
any irradiation (p<0.05; Figure 4). Although there was no 
significant difference in the survival of patients who had 
undergone hyperfractionated and standard radiotherapy, 
it seems that hyperfractionated irradiation could be more 
profitable, as in this group the relapses were less common: 
4 subjects (33.3%), as compared to 11 patients (57.9%) in 
standard radiotherapy group (Table III).
Figure 1. Overall survival according to disease stage
; (months)
Figure 3. Overall survival according to the response to the 1st 
chemotherapy cycle in patients with stage III and IV
Figure 2. Overall survival according to primary tum our localization Figure 4. Overall survival according to the perform ed radiotherapy
such param eters as: age (<10 years vs. >10 years, 
p=0.42), diagnosis (EES vs. PNET, p=0.51), tumour size 
(< 5  cm vs. >5 cm, p=0.38) and regional lymph node 
involvement (involved vs. non-involved, p=0.92).
As for response to the 1st chem otherapy cycle -  
better outcomes were observed in the case of children 
showing complete response or regression of over 2/3 of
Discussion
Ewing’s family tumours of soft tissue are rare childhood 
malignancies (the incidence in Poland is estim ated at 
approximately 4-5 new cases per year). Therefore only 
the cooperation of many paediatric and oncological 
centres allows to perform a reliable analysis of patient
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data. This study is a multicenter analysis of 11 years of 
experience of the Polish Pediatric Solid Tumours’ Group, 
which, to the best of our knowledge, is the first such an 
attempt in Poland.
The characteristics of our patient group are similar 
to those previously reported  in literature [9-13]. The 
tumours are most common in older children and in young 
adolescents, although sometimes they occur in very young 
patients or even in neonates [12]. There is no gender 
predominance. The most common locations are: the chest 
wall, the extrem ities and the head and neck region. 
Distant metastases predominantly involve the lungs and 
bones. However, it seems that in Polish children and 
adolescents the diagnosis was made relatively late, thus 
resulting in a m ore advance patients status. In most 
patients primary tumours were over 5 cm (75% in this 
study, as compared to 63% in the American group [11]). 
Moreover, radical primary resection was not possible in 
any patient and thus we enrolled no patients in stage I of 
the disease -  i.e. in the group with the best survival ratio 
[11, 12]. Similarly, the percentage of subjects in stage II 
was also lower (16%) than in other studies (23-27%) [11, 
12].
The more advanced stage of the disease could result 
in the poorer survival ratio of our group (5-year EFS 
39% and 5-year OS 44%) as compared to that reported 
by other authors (EFS 55-67%, OS 62-77%) [11, 13]. 
Although the complete remission ratio was high (over 
70%) and comparable to that reported in literature, yet 
the incidence of relapses (especially local) was very high. 
This could be explained by the fact that a relatively large 
group of patients (nearly 30%) were not irradiated. We 
have clearly dem onstrated that radiotherapy is an 
important element in the therapy of PNET and EES and 
significantly improved prognosis. Our observations are 
consistent with those of other authors [11, 14-16]. 
Interestingly, second-look surgery did not improve local 
control; this, in turn, contradicts literature data, according 
to which complete surgical excision reduces the risk of 
local reccurence, although it does not prevent metastatic 
spread [12]. However, in our patient group a majority of 
the resections were incomplete -  with microscopic, or 
even macroscopic, tumour residue. Moreover, the excision 
was predominantly perform ed in patients who showed 
poor response to chemotherapy, and therefore were at an 
increased risk of progression.
The stage of disease, gender and tumour localization 
were the most im portant factors affecting survival. 
Parameters such as tumour size and patient age had no 
impact on survival. We found this surprising, as these 
latter param eters are an element of the stratification of 
patients in the new CWS-2002P protocol [7]. Although 
our observations are similar to those reported by other 
authors, who had also stressed the importance of tumour 
localization and disease stage as the most im portant 
predictive values [11-13], yet some differences do meet 
the eye. Raney et al. [11] have reported the region of the 
head and neck, as well as the extremities, as the more 
favourable tumour locations. Zogopoulos et al. [13] have
reported that tumours localized within the extremities 
had had the best prognosis, while in our study tumours 
located on the extrem ities had the worst outcome. 
Moreover, in the study of Zogopoulos et al. [13] patients 
with primary pelvic tumours achieved very poor survival, 
while in the case of our study material this group had the 
most favourable outcome. A lthough our group is 
relatively small, this observation may suggest that our 
patients had, in fact, represented another population of 
children. Additionally, although Zogopoulos et al. have 
identified gender as a significant prognostic parameter, 
longer survivals characterised the boys (boys vs. girls 
survival ratio: 78.5% vs. 52.1%; p=0.007). In our group, 
boys had a less favorable outcome and we have failed to 
find any explanation for this discrepancy. As has already 
been demonstrated [17], we have confirmed that there 
were no significant differences in survival between EES 
and PNET.
The cooperation of Polish centres for paediatric 
oncology has resulted in the unification of the treatm ent 
modalities applied in the case of soft tissue sarcomas in 
children. A  significant improvement in survival was noted 
after the introduction of new protocol -  the CWS-96. We 
do hope, that new CWS-2002P protocol [7] will result in 
further im provem ent of prognosis in Polish children 
suffering from EES or PNET. The introduction of 
maintenance chemotherapy after intensive chemotherapy, 
which the CWS-96 protocol provides for patients with 
distant m etastases, could further improve survival in 
patients with PNET and EES. This may be supported by 
the results obtained in IRS groups [11], where a majority 
of patients are treated for a long period of time (81% of 
individuals were treated  for 2 years). M oreover, the 
introduction of a new treatm ent option could further 
improve patient prognosis [18-20].
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